​United States regulators have for the first time approved a drug that can slow the progression of Alzheimer’s disease, the most common type of dementia, offering hope for the growing pool of such patients here as well.

Current medications are able to treat just the symptoms of Alzheimer’s, a disease which robs patients of their memory and cognitive abilities as the cells in their brains that
process, store and retrieve information degenerate and die.

Known as aducanumab, the drug from US biotech firm Biogen is not available in Singapore, and can be used here only if approved by the Health Sciences Authority (HSA).

Click here for the full article.

Source: The Straits Times (c) Singapore Press Holdings. Permission required for reproduction.